Appointment Icon

UnityPoint Clinic - Express (Ankeny)

1055 Southwest Oralabor Road
Ankeny, IA 50023

Closed Patients
Waiting Now

UnityPoint Clinic - Express (Jordan Creek)

180 Jordan Creek Pkwy
West Des Moines, IA 50266

Closed Patients
Waiting Now

UnityPoint Clinic - Express (Waukee)

950 E Hickman Rd
Waukee, IA 50263

Closed Patients
Waiting Now

UnityPoint Clinic Behavioral Health Urgent Care - Des Moines

1250 East 9th Street
Des Moines, IA 50316

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Altoona

2720 8th Street Southwest
Altoona, IA 50009

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ankeny Medical Park

3625 North Ankeny Boulevard
Ankeny, IA 50023

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ingersoll

2103 Ingersoll Avenue
Des Moines, IA 50312

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Lakeview

6000 University Avenue
West Des Moines, IA 50266

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Merle Hay

4020 Merle Hay Road
Des Moines, IA 50310

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Southglen

6520 Southeast 14th Street
Des Moines, IA 50320

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Urbandale

5200 NW 100th Street
Urbandale, IA 50322

Closed Patients
Waiting Now
UnityPoint Health - John Stoddard Cancer Center

Prostate Cancer

  • Beginning at age 50, men should talk with their healthcare provider about beginning prostate-specific antigen (PSA) blood testing and digital rectal exams (DRE) of the prostate gland. Factors to consider are overall health of the individual and life-expectancy. To be most effective, the screening should include both the PSA and DRE.
  • Men who are in high-risk groups such as African Americans or men who have a history of prostate cancer in close family members (first-degree relative) should talk with their healthcare provider about beginning screenings at a younger age (45 years old).
  • Both men of average risk and high risk should be provided information about what is known and what is uncertain about the benefits and limitations of early detection and treatment of prostate cancer so that they can make an informed decision about testing.